Health phenome of Parkinson’s patients reveals prominent mood-sleep cluster

Background: Associations between phenotypic traits, environmental exposures, and Parkinson’s disease have largely been evaluated one-by-one, piecemeal, and pre-selections. A comprehensive picture of comorbidities, phenotypes, exposures, and polypharmacy characterizing the complexity and heterogeneity of real-world patients presenting to academic movement disorders clinics in the US is missing. Objectives: To portrait the complexity of features associated with patients with Parkinson’s disease in a study of 933 cases and 291 controls enrolled in the Harvard Biomarkers Study. Methods: The primary analysis evaluated 64 health features for associations with Parkinson’s using logistic regression adjusting for age and sex. We adjusted for multiple testing using the false discovery rate (FDR) with £ 0.05 indicating statistical significance. Exploratory analyses examined feature correlation clusters and feature combinations. Results: Depression (OR = 3.11, 95% CI 2.1 to 4.71), anxiety (OR = 3.31, 95% CI 2.01–5.75), sleep apnea (OR 2.58, 95% CI 1.47–4.92), and restless leg syndrome (RLS; OR 4.12, 95% CI 1.81–12.1) were significantly more common in patients with Parkinson’s than in controls adjusting for age and sex with FDR £ 0.05. The prevalence of depression, anxiety, sleep apnea, and RLS were correlated, and these diseases formed part of a larger cluster of mood traits and sleep traits linked to PD. Exposures to pesticides (OR 1.87, 95% CI 1.37–2.6), head trauma (OR 2.33, 95% CI 1.51–3.73), and smoking (OR 0.57, 95% CI 0.43–0.75) were significantly associated with the disease consistent with previous studies. Vitamin supplementation with cholecalciferol (OR 2.18, 95% CI 1.4–3.45) and coenzyme Q10 (OR 2.98, 95% CI 1.89–4.92) was more commonly used by patients than controls. Cumulatively, 43% (398 of 933) of Parkinson’s patients had at least one psychiatric or sleep disorder, compared to 21% (60 of 291) of healthy controls. Conclusions: 43% of Parkinson’s patients seen at Harvard-affiliated teaching hospitals have depression, anxiety, and disordered sleep. This syndromic cluster of mood and sleep traits may be pathophysiologically linked and clinically important.

[1]  Jae-Myung Kim,et al.  Restless legs syndrome affects sleep in de novo Parkinson’s disease patients , 2023, Medicine.

[2]  C. Vitale,et al.  Prevalence and clinical aspects of obstructive sleep apnea in Parkinson disease: A meta‐analysis , 2023, European journal of neurology.

[3]  P. Svenningsson,et al.  The noradrenergic subtype of Parkinson disease: from animal models to clinical practice , 2023, Nature Reviews Neurology.

[4]  C. Vitale,et al.  Sleep and wakefulness disturbances in Parkinson's disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. , 2023, Sleep medicine reviews.

[5]  K. Jellinger The pathobiological basis of depression in Parkinson disease: challenges and outlooks , 2022, Journal of Neural Transmission.

[6]  R. Postuma Neuroprotective Trials in REM Sleep Behavior Disorder , 2022, Neurology.

[7]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[8]  S. Saffari,et al.  Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis , 2022, Journal of Parkinson's disease.

[9]  I. Kouri,et al.  Restless Legs Syndrome and Periodic Limb Movements of Sleep: From Neurophysiology to Clinical Practice. , 2022, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[10]  T. Sakurai,et al.  Rapid eye movement sleep is initiated by basolateral amygdala dopamine signaling in mice , 2022, Science.

[11]  Shoji Nakamura Integrated pathophysiology of schizophrenia, major depression, and bipolar disorder as monoamine axon disorder. , 2022, Frontiers in bioscience.

[12]  Chieh-Sen Chuang,et al.  Association between β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis , 2021, Medicina.

[13]  Alejandro Osorio-Forero,et al.  Noradrenergic circuit control of non-REM sleep substates , 2021, Current Biology.

[14]  R. Barker,et al.  Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.

[15]  D. Brooks,et al.  Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. , 2020, Parkinsonism & related disorders.

[16]  P. De Deurwaerdère,et al.  The Noradrenergic System in Parkinson’s Disease , 2020, Frontiers in Pharmacology.

[17]  J. Growdon,et al.  Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. , 2020, Journal of Parkinson's disease.

[18]  Bilal A. Bari,et al.  Locus coeruleus-norepinephrine: basic functions and insights into Parkinson’s disease , 2019, Neural regeneration research.

[19]  D. Shin,et al.  Association of statin use with Parkinson's disease: Dose–response relationship , 2019, Movement disorders : official journal of the Movement Disorder Society.

[20]  J. Chen,et al.  Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease. , 2019, Neurotoxicology.

[21]  M. Nalls,et al.  The Parkinson’s phenome—traits associated with Parkinson’s disease in a broadly phenotyped cohort , 2019, npj Parkinson's Disease.

[22]  T. Friede,et al.  Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa) , 2018, Movement disorders : official journal of the Movement Disorder Society.

[23]  C. Glorioso,et al.  Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6 , 2018, Acta Neuropathologica Communications.

[24]  N. Gronich,et al.  β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[25]  F. Turkheimer,et al.  Serotonergic dysregulation is linked to sleep problems in Parkinson's disease , 2018, NeuroImage: Clinical.

[26]  P. Remy,et al.  High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study , 2018, European journal of neurology.

[27]  R. Marconi,et al.  Head trauma and Parkinson’s disease: results from an Italian case-control study , 2017, Neurological Sciences.

[28]  I. Roy,et al.  Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[29]  Nir Giladi,et al.  Statin adherence and the risk of Parkinson's disease: A population-based cohort study , 2017, PloS one.

[30]  Alison I. Bernstein,et al.  Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease , 2017, Proceedings of the National Academy of Sciences.

[31]  A. Ascherio,et al.  The epidemiology of Parkinson's disease: risk factors and prevention , 2016, The Lancet Neurology.

[32]  Zhiguo Sheng,et al.  Statin use and risk of Parkinson’s disease: A meta-analysis , 2016, Behavioural Brain Research.

[33]  Robert L. Sielken,et al.  Association between Parkinson’s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis , 2016, PloS one.

[34]  M. Weisskopf,et al.  Head injury at early ages is associated with risk of Parkinson's disease. , 2016, Parkinsonism & related disorders.

[35]  Cheng-Ta Li,et al.  Risk of developing Parkinson's disease among patients with asthma: a nationwide longitudinal study , 2015, Allergy.

[36]  K. Chaudhuri,et al.  The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review , 2015, npj Parkinson's Disease.

[37]  A. Nordström,et al.  Depression and subsequent risk of Parkinson disease , 2015, Neurology.

[38]  C. Tu,et al.  The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study. , 2014, QJM : monthly journal of the Association of Physicians.

[39]  Xiang Gao,et al.  Restless legs syndrome: an early clinical feature of Parkinson disease in men. , 2014, Sleep.

[40]  L. Marsh,et al.  Depression and Parkinson’s Disease: Current Knowledge , 2013, Current Neurology and Neuroscience Reports.

[41]  M. Harris,et al.  Head injuries and Parkinson's disease in a case-control study , 2013, Occupational and Environmental Medicine.

[42]  M. Etminan,et al.  Head injury and risk of Parkinson disease: A systematic review and meta‐analysis , 2013, Movement disorders : official journal of the Movement Disorder Society.

[43]  Honglei Chen,et al.  Head injury and Parkinson's disease: A population‐based study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[44]  A. Lees,et al.  Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.

[45]  K. Hirata,et al.  [Depression and anxiety in Parkinson's disease]. , 2012, Brain and nerve = Shinkei kenkyu no shinpo.

[46]  C. Tanner,et al.  Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.

[47]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[48]  Charles R. Yang,et al.  Current perspectives of the roles of the central norepinephrine system in anxiety and depression , 2010, Depression and anxiety.

[49]  J. Olsen,et al.  Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study , 2008, BMJ : British Medical Journal.

[50]  C. Nemeroff,et al.  The role of dopamine in the pathophysiology of depression. , 2007, Archives of general psychiatry.

[51]  J. Jankovic,et al.  Exploring the relationship between Parkinson disease and restless legs syndrome. , 2002, Archives of neurology.

[52]  W. Poewe,et al.  Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration , 1999, Movement disorders : official journal of the Movement Disorder Society.

[53]  M. Nefzger,et al.  A retrospective study of smoking in Parkinson's disease. , 1968, American journal of epidemiology.

[54]  D. Bansal,et al.  Statin use and risk of Parkinson’s disease: a meta-analysis of observational studies , 2012, Journal of Neurology.

[55]  S. Spangenberg,et al.  A nationwide population study of severe head injury and Parkinson's disease. , 2009, Parkinsonism & related disorders.

[56]  P. Vieregge,et al.  Transdermal nicotine in PD : A randomized , double-blind , placebo-controlled study , 2002 .